$ENVB

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update EB-003 Development Highlights: ● Advancing final IND-enabling activities to support the planned EB-003 IND application ● Completed IND-enabling absorption and metabolic

Enveric Biosciences reported a Q3 2026 net loss of $2.5M, improving from $3.4M a year earlier. Cash reserves stood at $5.6M. The company is advancing preclinical development of EB-003, targeting an IND submission and Phase 1 trial.

Enveric Biosciences (ENVB) reported preclinical qEEG study results for EB-003, showing brain activity modulation in mice. EB-003 demonstrated a differentiated profile from DMT, with no epileptic-like activity. The company plans to use qEEG as a biomarker in upcoming human trials, supporting EB-003's development for psychiatric and neurological disorders.

Enveric Biosciences reported positive in vitro ADMET results for EB-003, supporting progress toward a first-in-human trial. The company aims to advance the drug candidate with a planned IND filing.

Enveric Biosciences (ENVB) received a U.S. patent allowance for its EVM401 Series of non-hallucinogenic mescaline-derived compounds, designed to treat PTSD and other psychiatric disorders. This is the third patent in the series, covering novel methylone-inspired compounds. The company aims to strengthen its intellectual property portfolio and develop treatments that promote neuroplasticity without hallucinogenic effects.

Enveric Biosciences (ENVB) announced its CEO will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026. The presentation will update progress on EB-003, including IND-enabling studies and preclinical data. Dr. Tucker will also discuss the EVM401 Series and meet with investors.

Enveric Biosciences (NASDAQ: ENVB) reported Q2 2026 results and a corporate update. The company said EB-003 IND-enabling work advanced, including genotoxicity studies, and preclinical assays suggested a non-hallucinogenic and non-photoreactive profile. Enveric also received USPTO patent approvals and raised about $5.0M gross in a private placement plus $1.5M from warrant exercises. Net loss was $3.0M, cash $8.3M.

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: ● Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003

Enveric Biosciences said new preclinical tests using the Promega GloSensor cAMP live-cell assay show its lead psychiatric candidate EB-003 stays within a non-hallucinogenic profile versus hallucinogen and reference compounds. The company plans to advance EB-003 toward first-in-human Phase 1 trials. ENVB shares were down 7.69% to $1.56 premarket.

Enveric Biosciences Inc. (NASDAQ: ENVB) has successfully raised up to $13.9 million through a private placement, with an initial $5 million received upon closing. This funding, along with an additional $1.5 million from warrant exercises, will primarily support the preclinical development of its lead product candidate, EB-003, and facilitate the submission of an Investigational New Drug application. Despite a low GF Score™ of 28, indicating potential profitability challenges, the company boasts strong financial strength.